News from sellas life sciences group A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 02, 2017, 07:35 ET SELLAS Enters into a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc., Kenilworth, N.J., USA

SELLAS Life Sciences Group, Ltd. (SELLAS), a development-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of ...


Sep 14, 2017, 07:55 ET SELLAS' Galinpepimut-S Induces Specific, Robust and Durable Immune Responses in Patients With High-Risk Multiple Myeloma - Correlated With Clinical Benefit

SELLAS Life Sciences Group Ltd. (SELLAS), a privately-held, oncology-focused, clinical stage biopharmaceutical company, today reported that its...


Mar 01, 2017, 07:30 ET SELLAS Life Sciences Announces Updated Positive Phase 2 Data Reinforcing Meaningful Clinical Benefit of its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients

SELLAS Life Sciences Group (SELLAS or the Company), a late-stage biopharmaceutical company developing novel cancer immunotherapies for an extensive...


Feb 27, 2017, 07:00 ET Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy

Advaxis, Inc. (NASDAQ: ADXS) and SELLAS Life Sciences Group, both late-stage biopharmaceutical companies focused on developing cancer...


Dec 28, 2016, 09:31 ET SELLAS™ Life Sciences to Present at 35th Annual JP Morgan Healthcare Conference

SELLAS Life Sciences Group (SELLAS or the Company), a late-stage biopharmaceutical company developing novel cancer immunotherapies for a broad range...


Nov 17, 2016, 09:30 ET SELLAS™ Life Sciences Welcomes Internationally Renowned Experts in Immuno-Oncology to Scientific Advisory Board

SELLAS Life Sciences Group (SELLAS or the Company), a late-stage biopharmaceutical company developing novel cancer immunotherapies for a broad range...


Oct 19, 2016, 09:30 ET SELLAS™ Life Sciences Appoints Former Barclays Biotechnology Research Analyst as Chief Business and Strategy Officer

SELLAS Life Sciences Group (SELLAS or the Company), a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies ...


Oct 13, 2016, 09:30 ET SELLAS™ Life Sciences Announces Positive Interim Phase II Results from its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients

SELLAS Life Sciences Group (SELLAS or the Company), a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies ...


Oct 03, 2016, 09:30 ET SELLAS™ Life Sciences Appoints Industry Experts to Support Advancement of Cancer Therapeutics Pipeline

SELLAS Life Sciences Group (SELLAS or the Company), a development-stage biopharmaceutical company focused on developing innovative products to treat...


Sep 19, 2016, 09:30 ET SELLAS™ Life Sciences Receives FDA Fast Track Designation of Galinpepimut-S for the Treatment of Malignant Pleural Mesothelioma

SELLAS™ Life Sciences Group (SELLAS), a development-stage biopharmaceutical company focused on developing innovative products to treat cancer, today...


Sep 14, 2016, 09:05 ET SELLAS™ Life Sciences Announces Entry Into Cooperative Research and Development Agreement With National Heart, Lung and Blood Institute, National Institutes of Health

SELLAS Life Sciences Group (SELLAS or the Company), a development-stage biopharmaceutical company with its main focus on developing innovative...


Jun 06, 2016, 08:00 ET SELLAS™ Life Sciences Announces Exciting Results for Galinpepimut-S, the Company's WT1 Vaccine, in Patients with Acute Myeloid Leukemia (AML) and Malignant Pleural Mesothelioma (MPM), as Presented at the 2016 ASCO Annual Meeting

SELLAS™ Life Sciences Group (SELLAS™), a development-stage biopharmaceutical company with its main focus on developing innovative products to treat...


May 24, 2016, 08:00 ET SELLAS™ Life Sciences Announces Upcoming Presentation of Phase 2 Clinical Results for WT1 Cancer Vaccine at the 2016 ASCO Annual Meeting

SELLAS™ Life Sciences Group (SELLAS™), a development-stage biopharmaceutical company with its main focus on developing innovative products to treat...


May 04, 2016, 08:00 ET SELLAS Life Sciences Announces Positive WT1 Cancer Vaccine (galinpepimut-S) Clinical Results at the 13th International Conference of the International Mesothelioma Interest Group (iMig)

SELLAS Life Sciences Group (SELLAS), a development-stage biopharmaceutical company with its main focus on developing innovative products to treat...


May 02, 2016, 08:00 ET SELLAS Life Sciences Group Announces Initiation of Galinpepimut-S (WT1 Cancer Vaccine) Phase 1 Clinical Trial in Combination with PD-1 Checkpoint Inhibitor for Patients with Ovarian Cancer

SELLAS Life Sciences Group (SELLAS), a development-stage biopharmaceutical company with its main focus on developing innovative products to treat...


Apr 05, 2016, 09:00 ET SELLAS Life Sciences Group Receives a Favorable Opinion for European Orphan Drug Designations for WT1 Cancer Vaccine (galinpepimut-S) for the Treatment of Acute Myeloid Leukemia and for Malignant Pleural Mesothelioma

SELLAS Life Sciences Group (SELLAS), a development-stage biopharmaceutical company with its main focus on developing innovative products to treat...


Apr 01, 2016, 01:00 ET SELLAS Life Sciences to Present Phase 2 Clinical Results for WT1 Cancer Vaccine at the 2016 ASCO Annual Meeting and the 13th International Conference of the International Mesothelioma Interest Group (iMig)

SELLAS Life Sciences Group (SELLAS), a development-stage biopharmaceutical company with its main focus on developing innovative products to treat...


Mar 29, 2016, 08:00 ET SELLAS Receives USAN Approval for Generic Name of Galinpepimut-S for WT1 Vaccine, SELLAS's Late Clinical-Stage Cancer Immunotherapy Candidate

SELLAS Life Sciences Group (SELLAS), a development-stage biopharmaceutical company with its main focus on developing innovative products to treat...


Mar 01, 2016, 08:00 ET SELLAS Life Sciences Group to Present at the Cowen and Company 36th Annual Health Care Conference on Monday, March 7, 2016

SELLAS Life Sciences Group (SELLAS), a development-stage biopharmaceutical company with its main focus on developing innovative products to treat...


Feb 29, 2016, 08:00 ET SELLAS Life Sciences Announces FDA Orphan Drug Designation for WT1 Cancer Vaccine in Patients with Malignant Pleural Mesothelioma

SELLAS Life Sciences Group (SELLAS), a development-stage biopharmaceutical company focused on innovative products to treat cancers and central...


Jan 12, 2016, 08:00 ET SELLAS Life Sciences Announces Preliminary Positive WT1 Cancer Vaccine Clinical Results in Multiple Myeloma Patients

SELLAS Life Sciences Group (SELLAS), a development-stage biopharmaceutical company focused on innovative products to treat cancers and central...


Jan 11, 2016, 08:00 ET SELLAS Life Sciences Announces Orphan Drug Designation for WT1 Cancer Vaccine in Patients with Acute Myeloid Leukemia (AML)

SELLAS Life Sciences Group (SELLAS), a development-stage biopharmaceutical company focused on innovative products to treat cancers and central...


Jan 05, 2016, 08:00 ET SELLAS Life Sciences Group to Present at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016

SELLAS Life Sciences Group (SELLAS), a development-stage biopharmaceutical company with its main focus on developing innovative products to treat...


Dec 21, 2015, 08:00 ET SELLAS Life Sciences Expands Leadership Team, Appoints Andres A. Gutierrez, M.D., Ph.D., as Chief Medical Officer

SELLAS Life Sciences Group (SELLAS), a development-stage biopharmaceutical company focused on innovative products to treat cancers and central...


Nov 30, 2015, 08:00 ET SELLAS Life Sciences Reports Positive WT1 Cancer Vaccine Clinical Results in Mesothelioma and Acute Myeloid Leukemia (AML) Patients at the Annual International WT1 Conference

SELLAS Life Sciences Group (SELLAS), a development-stage biopharmaceutical company focused on innovative products to treat cancers and central...